SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
最近の投稿
- 1
IndiGo lands IATA chief Willie Walsh as new CEO - 2Family-Accommodating Snow Sports Experiences
- 3EU chief urges Iran to free imprisoned protesters, lift internet ban
- 4Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- 5‘Dying of thirst’: Inside Gaza’s al-Mawasi water crisis
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
- $1,000 bribes, Mormon momfluencer mixers and making content to get plastic surgery: The wildest things I learned reporting my book
- Fetterman says he's back home after a fall put the Pennsylvania senator in the hospital
- Which camera do you believe is great for first-time clients? !
- I'm a woman who's into weightlifting. Was I man enough for the creatine-packed 'Man Cereal'?
- Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
- Space debris: will it take a catastrophe for nations to take the issue seriously?
- Muslim nations condemn new Israeli death penalty law
